List of Excipients in Branded Drug FENSOLVI

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
TOLMAR Inc	FENSOLVI	leuprolide acetate	62935-163	METHYL PYRROLIDONE
TOLMAR Inc	FENSOLVI	leuprolide acetate	62935-163	POLY(DL-LACTIC-CO-GLYCOLIC ACID)

Fensolvi Excipient Strategy and Commercial Opportunities

Last updated: September 9, 2026

Fensolvi is a six-month subcutaneous depot formulation of leuprolide acetate for children with central precocious puberty. Its commercial differentiation depends less on the active ingredient than on the excipient system, biodegradable microsphere technology, injection usability, release control, and pediatric administration model. The core formulation uses poly(DL-lactide-co-glycolide), or PLGA, microspheres and N-methyl-2-pyrrolidone, or NMP, as the delivery vehicle.[1]

The strongest commercial opportunities are differentiated long-acting leuprolide products, improved pediatric injection systems, alternative biodegradable polymers, reduced injection volume, and manufacturing platforms that are difficult to replicate under an abbreviated regulatory pathway.

What excipients are used in Fensolvi?

Fensolvi contains leuprolide acetate encapsulated in biodegradable PLGA microspheres. NMP is used in the diluent system to suspend or reconstitute the microspheres before subcutaneous administration.[1]

Formulation element	Role in Fensolvi	Commercial relevance
Leuprolide acetate	GnRH agonist active ingredient	Generic active ingredient with limited standalone differentiation
PLGA microspheres	Biodegradable depot matrix	Controls drug release over approximately six months
NMP	Solvent and vehicle component	Supports polymer processing and injectability
Delivery syringe and needle system	Product administration	Affects reconstitution, injection force, handling and clinic workflow

PLGA is widely used in depot drug delivery because it hydrolyzes into lactic acid and glycolic acid. Polymer composition, molecular weight, end-group chemistry, particle size, porosity and drug loading can materially alter release kinetics.

NMP is commercially useful because it can dissolve or wet polymeric materials and support injectable depot formation. Its use also creates regulatory and product-development constraints. Residual solvent, local tolerability, container compatibility and injection-site safety require control.

How does the Fensolvi excipient system control drug release?

Fensolvi uses a biodegradable microsphere depot rather than a simple aqueous leuprolide suspension. After injection, the PLGA matrix gradually hydrates and degrades. Leuprolide is released through diffusion, polymer erosion and changes in microsphere structure.

Key formulation variables include:

• PLGA lactide-to-glycolide ratio
• Polymer molecular weight and viscosity
• Polymer end-group chemistry
• Microsphere diameter and distribution
• Drug loading
• Residual NMP level
• Water content
• Reconstitution time
• Injection-site depot geometry
• Storage temperature and container closure

A six-month release profile requires control of both early burst release and late-stage drug liberation. Excessive initial release can increase adverse effects and create subtherapeutic tail risks later in the dosing interval. Insufficient early release can delay pharmacodynamic suppression.

For a follow-on product, matching the leuprolide dose is not enough. A developer would need to characterize the full in vitro release profile, particle morphology, degradation behavior, pharmacokinetics and testosterone suppression profile.

What commercial advantages does the Fensolvi excipient strategy provide?

The excipient system creates several barriers that are more substantial than those associated with immediate-release leuprolide products.

Six-month dosing

Fensolvi reduces administration frequency compared with one-month or three-month depot products. In pediatric endocrinology, fewer injections can improve adherence, reduce clinic visits and lower treatment burden for families.

Pediatric administration

Fensolvi is administered subcutaneously. That route can be commercially attractive relative to intramuscular depot products, particularly when pediatric specialists prioritize smaller-gauge needles, simpler administration and reduced procedural burden.[1]

Product differentiation without a new active ingredient

Leuprolide is an established molecule. Fensolvi creates differentiation through delivery technology, dosing interval and administration profile. This allows value capture from formulation and device engineering even though the active ingredient is off-patent in its basic chemical form.

Clinic-centered purchasing

Fensolvi is administered by a healthcare professional. That supports specialty-pharmacy, buy-and-bill and endocrine-clinic distribution models. Commercial performance depends on reimbursement, acquisition cost, site-of-care economics and product handling as much as on prescription volume.

What formulation patents and intellectual-property barriers protect Fensolvi?

The commercially relevant intellectual property is likely concentrated in the depot formulation, manufacturing process, release profile, delivery configuration and methods of treating central precocious puberty. The active ingredient itself does not provide a meaningful long-term exclusivity barrier.

Formulation patent scope

Potential claim categories include:

• Leuprolide-loaded PLGA microspheres
• Specific polymer molecular-weight ranges
• Defined lactide-to-glycolide ratios
• Particle-size distributions
• Six-month release profiles
• NMP-containing injectable suspensions
• Reconstitution systems
• Subcutaneous administration methods
• Treatment of central precocious puberty using a six-month depot
• Manufacturing and drying processes
• Stability and container-closure configurations

The strongest claims are usually those that combine composition and performance limitations. A broad claim to “leuprolide in PLGA microspheres” may face prior-art pressure. A narrower claim tied to a defined release period, particle distribution, polymer specification and clinical pharmacodynamic outcome may be harder to design around but also easier to challenge for validity or infringement.

Manufacturing know-how

The practical barrier may be greater than the publicly visible patent estate. Important process variables include emulsification, solvent removal, microsphere hardening, drying, sterile processing, filling and reconstitution. Small process changes can affect residual solvent, burst release and syringeability.

A competitor may avoid literal infringement while still facing substantial development risk if it cannot reproduce the target release profile at commercial scale.

When does Fensolvi lose exclusivity?

Fensolvi was approved by the FDA on May 18, 2020, for pediatric patients with central precocious puberty.[2] The active ingredient, leuprolide acetate, predates Fensolvi by decades. Accordingly, the principal commercial protection is expected to arise from formulation, process, device and method-of-use rights rather than new-molecule exclusivity.

FDA approval status and Orange Book patent listings should be evaluated separately from patent expiration dates. Regulatory exclusivity can block certain approval pathways for a defined period, while patents can continue to restrict commercial marketing after regulatory exclusivity ends.[3]

Barrier	Relevance to Fensolvi
New chemical entity exclusivity	Not expected to be the principal protection because leuprolide is an established active ingredient
Clinical-investigation exclusivity	May apply to qualifying new clinical investigations, subject to FDA listing and expiration records
Pediatric exclusivity	May extend qualifying unexpired regulatory protections if granted
Formulation patents	Potentially central to follow-on product risk
Method-of-use patents	Relevant to central precocious puberty treatment claims
Device and process patents	Relevant to reconstitution, filling and manufacturing
Trade secrets	Important for microsphere production and scale-up

A definitive generic-entry date requires a current Orange Book review, patent-family analysis and litigation assessment. Public commercial strategy should not rely on approval date alone.

What generic entry risks exist for Fensolvi?

A conventional ANDA route may be difficult if a proposed product must demonstrate complex microsphere equivalence. The FDA may require extensive comparative characterization and, depending on the product and application, clinical evidence to establish equivalent performance.

Potential entry routes include:

1. A generic or follow-on leuprolide microsphere product with a comparable six-month profile.
2. A 505(b)(2) application using a different polymer, vehicle or delivery system.
3. A shorter-duration leuprolide product competing on price rather than dosing convenience.
4. A different GnRH agonist or antagonist product used in the same pediatric treatment pathway.
5. A device-led product that improves administration without fully matching the Fensolvi formulation.

The principal technical risks for a follow-on developer are burst release, incomplete drug release, injection-site tolerability, batch-to-batch variability and stability after reconstitution.

Which excipient strategies could create new commercial opportunities?

Alternative biodegradable polymers

Developers could evaluate polymers other than standard PLGA, including polyorthoesters, polylactic acid variants and other biodegradable matrices. The commercial objective would be to achieve six-month release with lower initial burst, less injection-site reaction or simpler manufacturing.

A new polymer system may support composition-of-matter and manufacturing claims, but it creates a larger toxicology and regulatory package.

Lower-volume formulations

A smaller injection volume could improve pediatric acceptance and reduce injection time. The tradeoff is higher drug concentration, greater microsphere loading and possible increases in viscosity or injection force.

Ready-to-use presentations

Fensolvi's reconstitution workflow creates opportunities for a prefilled or dual-chamber system. A ready-to-use product could reduce preparation errors and shorten clinic administration time.

Commercial value would depend on:

• Shelf-life improvement
• Reduced reconstitution steps
• Compatibility with the microsphere formulation
• Lower residual solvent exposure
• Device cost
• Needle and syringe performance

Needle and administration improvements

Potential enhancements include smaller-gauge needles, lower injection force, hidden-needle systems and integrated mixing mechanisms. Device claims can create a separate protection layer, although device differentiation must justify additional cost.

Extended dosing intervals

A nine-month or annual depot would have strong commercial appeal if it maintains reliable suppression and acceptable tolerability. The development burden would be substantial because the product must control prolonged release, late-stage dose dumping and treatment reversibility.

Excipient supplier partnerships

PLGA grade, molecular-weight consistency, residual-solvent control and sterile supply are strategic issues. A proprietary polymer grade or dedicated manufacturing agreement could reduce supply risk and support quality-by-design differentiation.

How does Fensolvi compare with competing leuprolide products?

Product category	Typical dosing concept	Administration	Main competitive advantage
Fensolvi	Six months	Subcutaneous injection	Long interval and pediatric-specific presentation
Monthly leuprolide depot	One month	Usually injectable depot	Lower formulation complexity and established use
Three-month depot	Three months	Injectable depot	Balance between convenience and market familiarity
Histrelin implant	Approximately one year	Subcutaneous implant	Long duration with one annual procedure
Alternative GnRH therapies	Varies	Injectable or oral, depending on product	Different administration or pharmacology

Fensolvi competes most directly with histrelin implants and other long-acting GnRH therapies in central precocious puberty. The decision can depend on procedure preference, reimbursement, local expertise, implant removal requirements and caregiver acceptance.

What is the FDA regulatory status of Fensolvi?

Fensolvi is FDA-approved for the treatment of central precocious puberty in pediatric patients two years of age and older.[1] The approved product is a six-month subcutaneous depot injection administered by a healthcare professional.

The regulatory strategy for a competing excipient system would depend on how closely the proposed product matches Fensolvi. A product with the same active ingredient but materially different excipients, release mechanism or route may require a 505(b)(2) pathway rather than a straightforward ANDA. The pathway affects clinical requirements, patent certifications, labeling and launch timing.[4]

Biosimilar risk is not relevant in the conventional sense. Fensolvi is a synthetic small-molecule peptide product, not a biologic requiring a biosimilar pathway. Competitive risk is more likely to come from generic, 505(b)(2), device-based or alternative GnRH products.

What licensing and partnering opportunities exist?

Commercial opportunities are strongest for companies with one of four capabilities:

• Long-acting injectable formulation technology
• Sterile microsphere manufacturing
• Pediatric specialty commercialization
• Drug-device combination development

A license covering PLGA microsphere production, solvent handling, sterile filling or reconstitution technology could reduce development time. A regional partnership could also be attractive because central precocious puberty treatment is specialist-driven and reimbursement differs substantially by country.

Potential deal structures include an upfront payment for platform access, milestone payments tied to pharmacokinetic or regulatory outcomes, manufacturing supply rights and territorial commercialization options.

What is the revenue exposure and market opportunity?

Tolmar is a private company, and product-level Fensolvi revenue is not separately disclosed in the FDA approval materials. Revenue analysis therefore requires company disclosures, payer data or prescription and shipment datasets rather than relying on public FDA records.

The product's commercial drivers are measurable:

• Number of diagnosed children receiving GnRH therapy
• Share of patients treated with six-month depots
• Net price after rebates and channel discounts
• Specialty-pharmacy penetration
• Buy-and-bill reimbursement
• Persistence through puberty-management treatment
• Competitive conversion from monthly or quarterly products

A follow-on product could compete through lower net price, reduced administration cost, lower injection burden or improved reimbursement positioning. Price competition alone may be insufficient if clinics value the six-month dosing interval and established product workflow.

Key Takeaways

• Fensolvi's central differentiator is its six-month PLGA microsphere depot, not leuprolide itself.
• PLGA controls degradation and release, while NMP supports the injectable depot system.
• The principal follow-on barriers are formulation equivalence, manufacturing scale-up, release kinetics, device performance and patent scope.
• The strongest commercial opportunities are ready-to-use systems, lower-volume injections, improved needles, alternative biodegradable polymers and longer dosing intervals.
• Fensolvi is a small-molecule peptide product, so biosimilar competition is not the relevant risk category.
• A generic or 505(b)(2) competitor would need to address burst release, residual solvent, injection-site tolerability and six-month pharmacodynamic control.
• Exact launch timing depends on current Orange Book listings, patent-family analysis, regulatory exclusivity and any litigation or settlement activity.

FAQs

Can NMP be replaced in a Fensolvi follow-on formulation?

Yes. A developer could evaluate alternative solvents or aqueous-polymer systems, but replacement would alter microsphere formation, residual-solvent control, injection force, stability and local tolerability. The alternative would require its own regulatory and intellectual-property strategy.

Is PLGA the only polymer that can provide six-month leuprolide release?

No. Other biodegradable polymer systems may provide comparable duration, but they would require independent development of release kinetics, safety, manufacturing controls and regulatory comparability.

Would a prefilled Fensolvi-style product have commercial value?

Yes. A prefilled or dual-chamber presentation could reduce reconstitution steps and administration time. Its value would depend on shelf life, device cost, microsphere stability and reliable dose delivery.

Is a six-month leuprolide product eligible for an ANDA?

Possibly, but the pathway depends on the degree of formulation and performance similarity. A materially different depot system may require a 505(b)(2) application and additional clinical evidence.

What is the most defensible patent position for a competing excipient system?

A layered position combining polymer composition, microsphere characteristics, release profile, manufacturing process, device configuration and pediatric method-of-use claims is generally stronger than a single broad formulation claim.

References

1. U.S. Food and Drug Administration. (2024). Fensolvi (leuprolide acetate) for injectable suspension prescribing information.
2. U.S. Food and Drug Administration. (2020). FDA approves Fensolvi for pediatric patients with central precocious puberty.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).